▲ +5.40% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Sientra in the last 3 months. The average price target is $8.20, with a high forecast of $11.00 and a low forecast of $5.00. The average price target represents a 5.40% upside from the last price of $7.78.
The current consensus among 6 investment analysts is to buy stock in Sientra. This Buy consensus rating has held steady for over two years.
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, OPUS, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline filled breast implant sizers; and miraDry System, a non-surgical device for the permanent reduction of underarm sweat, odor, and hair of all colors. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.